Serum IgG levels as biomarkers for optimizing IVIg therapy in CIDP

Journal of the Peripheral Nervous System

Volumn 16, Issue SUPPL. 1, 2011, Pages 38-40

  Van Doorn, Pieter A ^a   Kuitwaard, Krista ^a   Jacobs, Bart C ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

biomarker; CIDP; GBS; IgG; IVIg

Indexed keywords

BIOLOGICAL MARKER; IMMUNOGLOBULIN; IMMUNOGLOBULIN G;

ARTICLE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CLINICAL TRIAL (TOPIC); DISABILITY; DISEASE ACTIVITY; DRUG MONITORING; ERASMUS GBS OUTCOME SCALE; GUILLAIN BARRE SYNDROME; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOTHERAPY; MAINTENANCE THERAPY; OPTIMAL DRUG DOSE; PATIENT SELECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RATING SCALE; STANDARDIZATION; TREATMENT RESPONSE;

BIOLOGICAL MARKERS; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULINS, INTRAVENOUS; POLYRADICULONEUROPATHY, CHRONIC INFLAMMATORY DEMYELINATING; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 79959619871     PISSN: 10859489     EISSN: 15298027     Source Type: Journal    
DOI: 10.1111/j.1529-8027.2011.00304.x     Document Type: Article

References (16)

1. Asbury AK, Cornblath DR, (1990). Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 27: S21-S24. (Pubitemid 20178648)
2. van Doorn PA, (2005). Treatment of Guillain-Barré syndrome and CIDP. J Peripher Nerv Syst 10: 113-127.
3. van Doorn PA, Ruts L, Jacobs BC, (2008). Clinical features, pathogenesis, and treatment of Guillain-Barré syndrome. Lancet Neurol 7: 939-950.
4. van Doorn PA, Kuitwaard K, Walgaard C, van Koningsveld R, Ruts L, Jacobs BC, (2010). IVIg treatment and prognosis in Guillain-Barré syndrome. J Clin Immunol 30(Suppl 1): S74-S78.
5. Eftimov F, Winer JB, Vermeulen M, de Haan R, van Schaik IN, (2009). Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy. Cochrane Database Syst Rev 1: CD001797.
6. Farcas P, Avnun L, Frisher S, Herishanu YO, Wirguin I, (1997). Efficacy of repeated intravenous immunoglobulin in severe unresponsive Guillain-Barré syndrome. Lancet 350: 1747. (Pubitemid 28036676)
7. Hughes RA, Donofrio P, Bril V, Dalakas MC, Deng C, Hanna K, Hartung HP, Latov N, Merkies IS, van Doorn PA, (2008). Intravenous immune globulin (10% caprylate-chromatography purified) for the treatment of chronic inflammatory demyelinating polyradiculoneuropathy (ICE study): a randomised placebo-controlled trial. Lancet Neurol 7: 136-144.
8. Hughes RA, Swan AV, Raphael JC, Annane D, van Koningsveld R, van Doorn PA, (2007). Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain 130: 2245-2257. (Pubitemid 47327619)
9. Joint Task Force of the EFNS and the PNS (2010). European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society-First Revision. J Peripher Nerv Syst 15: 1-9.
10. van Koningsveld R, Steyerberg EW, Hughes RA, Swan AV, van Doorn PA, Jacobs BC, (2007). A clinical prognostic scoring system for Guillain- Barré syndrome. Lancet Neurol 6: 589-594. (Pubitemid 46921042)
11. Kuitwaard K, de Gelder J, Tio-Gillen AP, Hop WC, van Gelder T, van Toorenenbergen AW, van Doorn PA, Jacobs BC, (2009). Pharmacokinetics of intravenous immunoglobulin and outcome in Guillain-Barré syndrome. Ann Neurol 66: 597-603.
12. Kuitwaard K, van den Berg LH, Vermeulen M, Brusse E, Cats EA, van der Kooi AJ, Notermans NC, van der Pol WL, van Schaik IN, van Nes SI, Hop WC, van Doorn PA, (2010). Randomised controlled trial comparing two different intravenous immunoglobulins in chronic inflammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 81: 1374-1379.
13. Latov N, Deng C, Dalakas MC, Bril V, Donofrio P, Hanna K, Hartung HP, Hughes RA, Merkies IS, van Doorn PA, (2010). Timing and course of clinical response to intravenous immunoglobulin in chronic inflammatory demyelinating polyradiculoneuropathy. Arch Neurol 67: 802-807.
14. Ruts L, Drenthen J, Jacobs BC, van Doorn PA, (2010). Distinguishing acute-onset CIDP from fluctuating Guillain-Barré syndrome: a prospective study. Neurology 74: 1680-1686.
15. Walgaard C, Lingsma HF, Ruts L, Drenthen J, van Koningsveld R, Garssen MJ, van Doorn PA, Steyerberg EW, Jacobs BC, (2010). Prediction of respiratory insufficiency in Guillain-Barré syndrome. Ann Neurol 67: 781-787.
16. Walgaard C, Lingsma HF, Ruts L, van Doorn PA, Steyerberg EW, Jacobs BC, (2011). Early recognition of poor prognosis in Guillain-Barré syndrome. Neurology 76: 968-975.